vs

Side-by-side financial comparison of UTAH MEDICAL PRODUCTS INC (UTMD) and VALUE LINE INC (VALU). Click either name above to swap in a different company.

UTAH MEDICAL PRODUCTS INC is the larger business by last-quarter revenue ($9.0M vs $8.3M, roughly 1.1× VALUE LINE INC). VALUE LINE INC runs the higher net margin — 71.4% vs 28.4%, a 43.0% gap on every dollar of revenue. On growth, UTAH MEDICAL PRODUCTS INC posted the faster year-over-year revenue change (-1.2% vs -7.7%). Over the past eight quarters, VALUE LINE INC's revenue compounded faster (-4.1% CAGR vs -10.7%).

Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...

Value Line, Inc. is a publicly traded investment research and financial publishing firm based in New York City. Founded in 1931 by Arnold Bernhard, Value Line is best known for publishing The Value Line Investment Survey, a stock analysis newsletter that tracks approximately 1,700 publicly traded stocks.

UTMD vs VALU — Head-to-Head

Bigger by revenue
UTMD
UTMD
1.1× larger
UTMD
$9.0M
$8.3M
VALU
Growing faster (revenue YoY)
UTMD
UTMD
+6.5% gap
UTMD
-1.2%
-7.7%
VALU
Higher net margin
VALU
VALU
43.0% more per $
VALU
71.4%
28.4%
UTMD
Faster 2-yr revenue CAGR
VALU
VALU
Annualised
VALU
-4.1%
-10.7%
UTMD

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
UTMD
UTMD
VALU
VALU
Revenue
$9.0M
$8.3M
Net Profit
$2.6M
$5.9M
Gross Margin
58.2%
Operating Margin
27.0%
12.1%
Net Margin
28.4%
71.4%
Revenue YoY
-1.2%
-7.7%
Net Profit YoY
-11.6%
14.5%
EPS (diluted)
$0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
UTMD
UTMD
VALU
VALU
Q1 26
$8.3M
Q4 25
$9.0M
$8.6M
Q3 25
$9.8M
$8.6M
Q2 25
$10.0M
$8.4M
Q1 25
$9.7M
$9.0M
Q4 24
$9.2M
$8.8M
Q3 24
$10.0M
$8.9M
Q2 24
$10.4M
$9.0M
Net Profit
UTMD
UTMD
VALU
VALU
Q1 26
$5.9M
Q4 25
$2.6M
$5.7M
Q3 25
$2.6M
$6.5M
Q2 25
$3.0M
$4.0M
Q1 25
$3.0M
$5.2M
Q4 24
$2.9M
$5.7M
Q3 24
$3.6M
$5.9M
Q2 24
$3.5M
$4.8M
Gross Margin
UTMD
UTMD
VALU
VALU
Q1 26
Q4 25
58.2%
Q3 25
57.1%
Q2 25
56.2%
Q1 25
57.0%
Q4 24
58.1%
Q3 24
58.0%
Q2 24
60.1%
Operating Margin
UTMD
UTMD
VALU
VALU
Q1 26
12.1%
Q4 25
27.0%
17.7%
Q3 25
26.6%
17.4%
Q2 25
32.1%
9.9%
Q1 25
32.5%
17.4%
Q4 24
32.0%
19.7%
Q3 24
33.4%
20.8%
Q2 24
33.1%
16.5%
Net Margin
UTMD
UTMD
VALU
VALU
Q1 26
71.4%
Q4 25
28.4%
66.4%
Q3 25
26.8%
75.1%
Q2 25
30.6%
47.1%
Q1 25
31.3%
57.6%
Q4 24
31.7%
64.3%
Q3 24
35.6%
66.3%
Q2 24
33.2%
53.1%
EPS (diluted)
UTMD
UTMD
VALU
VALU
Q1 26
Q4 25
$0.80
Q3 25
$0.82
Q2 25
$0.94
Q1 25
$0.92
Q4 24
$0.86
Q3 24
$1.03
Q2 24
$0.98

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
UTMD
UTMD
VALU
VALU
Cash + ST InvestmentsLiquidity on hand
$85.8M
$92.5M
Total DebtLower is stronger
$225.0K
Stockholders' EquityBook value
$119.3M
$107.8M
Total Assets
$122.5M
$151.0M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
UTMD
UTMD
VALU
VALU
Q1 26
$92.5M
Q4 25
$85.8M
$86.6M
Q3 25
$84.3M
$33.7M
Q2 25
$82.2M
$67.7M
Q1 25
$83.3M
$52.8M
Q4 24
$83.0M
$22.3M
Q3 24
$88.5M
$30.9M
Q2 24
$89.2M
$4.4M
Total Debt
UTMD
UTMD
VALU
VALU
Q1 26
Q4 25
$225.0K
Q3 25
Q2 25
Q1 25
$269.0K
Q4 24
$282.0K
Q3 24
Q2 24
Stockholders' Equity
UTMD
UTMD
VALU
VALU
Q1 26
$107.8M
Q4 25
$119.3M
$105.5M
Q3 25
$118.3M
$103.0M
Q2 25
$117.5M
$99.7M
Q1 25
$117.0M
$99.0M
Q4 24
$117.4M
$96.7M
Q3 24
$124.2M
$93.9M
Q2 24
$124.1M
$90.8M
Total Assets
UTMD
UTMD
VALU
VALU
Q1 26
$151.0M
Q4 25
$122.5M
$147.9M
Q3 25
$122.0M
$148.2M
Q2 25
$120.8M
$144.5M
Q1 25
$122.5M
$143.6M
Q4 24
$122.5M
$140.0M
Q3 24
$129.7M
$138.6M
Q2 24
$130.0M
$136.0M
Debt / Equity
UTMD
UTMD
VALU
VALU
Q1 26
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
0.00×
Q4 24
0.00×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
UTMD
UTMD
VALU
VALU
Operating Cash FlowLast quarter
$3.5M
$5.3M
Free Cash FlowOCF − Capex
$3.4M
FCF MarginFCF / Revenue
37.2%
Capex IntensityCapex / Revenue
1.2%
0.0%
Cash ConversionOCF / Net Profit
1.36×
0.89×
TTM Free Cash FlowTrailing 4 quarters
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
UTMD
UTMD
VALU
VALU
Q1 26
$5.3M
Q4 25
$3.5M
$3.0M
Q3 25
$3.9M
$5.6M
Q2 25
$2.9M
$20.2M
Q1 25
$4.5M
$6.9M
Q4 24
$2.9M
$3.1M
Q3 24
$3.9M
$4.8M
Q2 24
$2.8M
$17.9M
Free Cash Flow
UTMD
UTMD
VALU
VALU
Q1 26
Q4 25
$3.4M
Q3 25
$3.9M
Q2 25
$2.8M
$20.1M
Q1 25
$4.3M
$6.8M
Q4 24
$2.9M
$3.0M
Q3 24
$3.8M
$4.8M
Q2 24
$2.7M
$17.9M
FCF Margin
UTMD
UTMD
VALU
VALU
Q1 26
Q4 25
37.2%
Q3 25
39.2%
Q2 25
28.4%
239.2%
Q1 25
44.1%
75.3%
Q4 24
32.0%
34.1%
Q3 24
37.7%
53.7%
Q2 24
25.5%
199.0%
Capex Intensity
UTMD
UTMD
VALU
VALU
Q1 26
0.0%
Q4 25
1.2%
0.0%
Q3 25
0.3%
0.0%
Q2 25
0.5%
2.1%
Q1 25
1.9%
1.2%
Q4 24
0.1%
0.7%
Q3 24
0.9%
0.0%
Q2 24
1.1%
0.2%
Cash Conversion
UTMD
UTMD
VALU
VALU
Q1 26
0.89×
Q4 25
1.36×
0.52×
Q3 25
1.47×
0.86×
Q2 25
0.94×
5.12×
Q1 25
1.47×
1.33×
Q4 24
1.01×
0.54×
Q3 24
1.08×
0.81×
Q2 24
0.80×
3.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons